Home Biomarkers Anti Nuclear Antibodies (ANA)

Anti Nuclear Antibodies (ANA)

Autoimmune disorder Biomarker

Sample Needed

Collection Type: Blood

Body System

Related System: Autoimmune disorder

Overview

Anti‑nuclear antibodies (ANA) are autoantibodies that target components of the cell nucleus. The ANA test detects these antibodies using indirect immunofluorescence (titer and pattern) or immunoassays (units). It is a general screening test for systemic autoimmune connective‑tissue diseases such as systemic lupus erythematosus (SLE), Sjögren’s syndrome, systemic sclerosis, mixed connective tissue disease and drug‑induced lupus; clinicians also order it for unexplained arthralgia, rash, photosensitivity, Raynaud’s phenomenon, mucosal ulcers or unexplained organ inflammation. Positive ANAs are more common in females and increase with age; low titers can be seen in healthy people, infections or malignancy, so interpretation depends on titer, pattern and clinical context.

People also test for

Test Preparation

No special preparation is required

Why Do I Need This Test

Which profile is the test included in: Autoimmune disorder profile.
What symptoms may indicate a need for this test: persistent joint pain, unexplained rash, photosensitivity, chronic fatigue, Raynaud’s, recurrent fevers, muscle weakness, organ inflammation.
What conditions it may diagnose/monitor: SLE, Sjögren’s, systemic sclerosis, MCTD, autoimmune hepatitis, drug‑induced lupus.
What could be the reasons for abnormal levels: autoimmune disease, certain infections, some malignancies, or drug exposure.
Biological meaning of abnormal values: presence of an immune response against nuclear components suggesting systemic autoimmunity.
What behaviors/lifestyle can cause abnormal values: specific drugs (e.g., hydralazine, procainamide, isoniazid), chronic infections; general lifestyle factors (smoking, UV exposure) may influence disease activity but are not direct causes of ANA.
What family history may indicate a need for the test: first‑degree relatives with autoimmune connective‑tissue diseases increases pretest probability.

Run our symptom checker to see if this test is right for you

Symptom Checker

Understanding Test Results

A negative ANA (<1:40 or <20 U) makes systemic autoimmune connective‑tissue disease less likely but does not exclude it.
Low‑positive titers (1:40–1:80) are frequently nonspecific and can occur in healthy individuals, older adults, infections or drug exposure.
Moderate titers (≥1:160) raise suspicion for systemic autoimmune disease and warrant evaluation for disease‑specific antibodies (anti‑dsDNA, anti‑Sm, anti‑Ro/La, Scl‑70, centromere).
High titers (≥1:320 to ≥1:640) or very high titers (>1:1280) strongly support an autoimmune etiology and correlate with higher likelihood of active disease; pattern (homogeneous, speckled, nucleolar, centromere) and follow‑up specific antibody testing determine diagnosis and management.
Persistent positivity should be interpreted with clinical findings; isolated low positive ANA without symptoms often requires watchful waiting rather than immediate treatment.

Normal Range

<1:40 (titer) OR <20 U (ELISA)

FAQs

Q: What cancers cause ANA positive?

A: Antinuclear antibodies (ANA) may be positive in some cancers, especially hematologic malignancies (lymphomas, leukemias, multiple myeloma) and various solid tumors such as lung, breast, ovarian, colorectal, hepatic and prostate cancers. ANA positivity is nonspecific and can reflect paraneoplastic autoimmune phenomena, tumor-related immune activation, or treatment effects; abnormal results warrant clinical correlation and appropriate oncologic evaluation.

Q: When do you worry about ANA levels?

A: Be concerned about ANA results when titers are high (commonly ≥1:160), rise over time, or show disease-specific staining patterns, especially if accompanied by symptoms such as persistent fatigue, joint pain, rashes (including photosensitivity), oral ulcers, unexplained fevers, or organ dysfunction. Concern increases when other autoimmune markers or abnormal labs (low complement, positive anti-dsDNA/anti‑Sm, high ESR/CRP) are present—prompt specialist review is advised.

Q: What is the most common reason for positive ANA?

A: The most common reason for a positive antinuclear antibody (ANA) test is an underlying systemic autoimmune disease, most frequently systemic lupus erythematosus (SLE). However, low‑titer ANA positivity can also occur in healthy people—particularly older adults—or with infections, certain medications (drug‑induced lupus), and other inflammatory conditions. Test results must be interpreted alongside symptoms, clinical exam, and further specific autoantibody tests.

Q: What is the next step after a positive ANA test?

A: After a positive ANA test, clinicians correlate the result with symptoms and perform targeted follow‑up: specific autoantibody panels (anti‑dsDNA, anti‑Sm, anti‑Ro/SSA, anti‑La/SSB, anti‑RNP), inflammatory markers (ESR, CRP), complement levels and urinalysis to assess organ involvement. Repeat titers may be done. Referral to a rheumatologist for comprehensive evaluation and diagnosis is often recommended.

Q: Is ANA-positive curable?

A: A positive ANA is a lab finding, not a disease, so it isn’t “curable.” Treatment focuses on any underlying autoimmune disorder and can control symptoms and disease activity; antibody levels may fall but often persist. Some people have transient ANA positivity (after infection or medication) and revert to negative. If ANA is positive, evaluation and follow-up with a clinician are recommended to determine cause and management.

Q: How much ANA is normal?

A: ANA is reported as a titer and pattern; most labs consider results below 1:40 (some use 1:80) as negative. Low positive titers (1:40–1:80) can occur in healthy people, especially older adults. Higher titers (≥1:160) are more suggestive of autoimmune disease but must be interpreted with clinical symptoms and followed by specific antibody testing.